Inclusion Criteria:

1. Women ≥ 18 years of age

2. Histologically confirmed endometrial cancer

3. Advanced (FIGO stage III or IV), recurrent or metastatic disease.

4. Measurable or non-measurable disease that has progressed since last treatment.

5. Patients who have progressed after prior first line treatment with platinum/taxane
based chemotherapy for advanced, recurrent or metastatic endometrial cancer.

6. Availability of fresh or archival FFPE tumor specimens for analysis of LHRH receptor
expression.

Exclusion Criteria:

1. ECOG performance status > 2.

2. Inadequate hematologic, hepatic or renal function

3. Red blood cell transfusion within 2 weeks prior to anticipated start of study
treatment.

4. History of myocardial infarction, unstable angina, or uncontrolled arrhythmia within
the past 6 months.

5. Impaired cardiac function defined as left ventricular ejection fraction (LVEF) < 50 %
as measured by MUGA or ECHO.

6. Planned concomitant use of potentially cardiotoxic medication

7. Chemo-, immune-, hormone-, or radiotherapy (including pre- or post-operative
brachytherapy) within 4 weeks prior to randomization.

8. Previous anthracycline-based chemotherapy.

9. Anticipated ongoing concomitant anticancer therapy during the study.

10. History of serious co-morbidity or uncontrolled illness that would preclude study
therapy, such as active tuberculosis or any other active infection.

11. Brain metastasis, leptomeningeal disease.

12. Pregnant or lactating female or female of child-bearing potential not employing
adequate contraception.

13. Receipt of 2 or more prior chemotherapy regimens for advanced, recurrent, or
metastatic endometrial cancer.

14. Prior treatment with AEZS-108.

15. Use of LHRH agonist or antagonist treatment within 6 months prior to randomization.

16. Malignancy within last 5 years except non-melanoma skin cancer.

17. Any concomitant disease or condition which would interfere with the subjects' proper
completion of the protocol assignment.

18. Concomitant or recent treatment with other investigational drug (within 8 weeks or 5
elimination half life times prior to anticipated start of study treatment).

19. Lack of ability or willingness to give informed consent.

20. Anticipated non-availability for study visits/procedures.